Home
  >  
Section 40
  >  
Chapter 39,961

Effects of bestatin on myelopoietic stem cells in normal and cyclophosphamide-treated mice

Abe, F.; Matsuda, A.; Schneider, M.; Talmadge, J.E.

Cancer Immunology Immunotherapy Cii 32(2): 75-80

1990


ISSN/ISBN: 0340-7004
PMID: 2289207
DOI: 10.1007/bf01754202
Accession: 039960302

Download citation:  
Text
  |  
BibTeX
  |  
RIS

The effect of bestatin on hematopoietic parameters and bone marrow progenitor activity (colony-forming unit - granulocyte/macrophage: CFU-GM) was examined in normal and myelosuppressed C57BL/6 mice. CFU-GM frequency and absolute number were determined with a limiting dilution analysis of bone marrow cells in soft agar using recombinant murine colony-stimulating factor - granulocyte/macrophage. We report that bestatin increased splenic, bone marrow, and peripheral blood cellularity and the number of CFU-GM over a dose range from 2.5 mg/kg through 100 mg/kg following i.p., i.v., or oral administration. The greatest myeloid stimulation was observed following multiple injections of bestatin. Bestatin also increased the recovery from cyclophosphamide-induced myelodepression as measured by these parameters. The hematopoietic properties of bestatin following oral administration is of potential importance for clinical application.

PDF emailed within 0-6 h: $19.90